Literature DB >> 29049853

Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.

Ilhan Akan1, Stephanie Olivier-Van Stichelen1, Michelle R Bond1, John A Hanover1.   

Abstract

Proteostasis is essential in the mammalian brain where post-mitotic cells must function for decades to maintain synaptic contacts and memory. The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation. In this review, we outline how the nutrient-sensitive nucleocytoplasmic post-translational modification O-linked N-acetylglucosamine (O-GlcNAc) regulates protein homeostasis. The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. C. elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease. These enzymes add and remove the single monosaccharide from protein serine and threonine residues, respectively. Blocking O-GlcNAc cycling is detrimental to mammalian brain development and interferes with neurogenesis, neural migration, and proteostasis. Findings in C. elegans and Drosophila model systems indicate that the dynamic turnover of O-GlcNAc is critical for maintaining levels of key transcriptional regulators responsible for neurodevelopment cell fate decisions. In addition, pathways of autophagy and proteasomal degradation depend on a transcriptional network that is also reliant on O-GlcNAc cycling. Like the quality control system in the endoplasmic reticulum which uses a 'mannose timer' to monitor protein folding, we propose that cytoplasmic proteostasis relies on an 'O-GlcNAc timer' to help regulate the lifetime and fate of nuclear and cytoplasmic proteins. O-GlcNAc-dependent developmental alterations impact metabolism and growth of the developing mouse embryo and persist into adulthood. Brain-selective knockout mouse models will be an important tool for understanding the role of O-GlcNAc in the physiology of the brain and its susceptibility to neurodegenerative injury. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Alzheimer's; Glucose; Neurodegeneration; O-GlcNAc; O-linked N-acetylglucosamine; Therapeutics

Mesh:

Substances:

Year:  2017        PMID: 29049853      PMCID: PMC5735008          DOI: 10.1111/jnc.14242

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  326 in total

1.  Central action of insulin regulates pulsatile luteinizing hormone secretion in the diabetic sheep model.

Authors:  T Tanaka; S Nagatani; D C Bucholtz; S Ohkura; H Tsukamura; K Maeda; D L Foster
Journal:  Biol Reprod       Date:  2000-05       Impact factor: 4.285

2.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Authors:  Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

3.  A monoclonal antibody against a family of nuclear pore proteins (nucleoporins): O-linked N-acetylglucosamine is part of the immunodeterminant.

Authors:  M K Park; M D'Onofrio; M C Willingham; J A Hanover
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

4.  Localization of O-GlcNAc-modified proteins in neuromuscular diseases.

Authors:  Seika Nakamura; Satoshi Nakano; Makoto Nishii; Satoshi Kaneko; Hirofumi Kusaka
Journal:  Med Mol Morphol       Date:  2012-06-21       Impact factor: 2.309

5.  O-linked N-acetylglucosamine levels in cerebellar neurons respond reciprocally to pertubations of phosphorylation.

Authors:  L S Griffith; B Schmitz
Journal:  Eur J Biochem       Date:  1999-06

6.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

Authors:  Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Gerald W Hart; Cheng-Xin Gong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

7.  O-GlcNAc cycling shows neuroprotective potential in C. elegans models of neurodegenerative disease.

Authors:  John A Hanover; Peng Wang
Journal:  Worm       Date:  2013-11-12

8.  Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation.

Authors:  Markus Schubert; Derek P Brazil; Deborah J Burks; Jake A Kushner; Jing Ye; Carrie L Flint; Janet Farhang-Fallah; Pieter Dikkes; Xavier M Warot; Carlos Rio; Gabriel Corfas; Morris F White
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

Review 9.  Chemical arsenal for the study of O-GlcNAc.

Authors:  Eun J Kim
Journal:  Molecules       Date:  2011-02-28       Impact factor: 4.411

10.  Serum-stimulated cell cycle entry promotes ncOGT synthesis required for cyclin D expression.

Authors:  S Olivier-Van Stichelen; L Drougat; V Dehennaut; I El Yazidi-Belkoura; C Guinez; A-M Mir; J-C Michalski; A-S Vercoutter-Edouart; T Lefebvre
Journal:  Oncogenesis       Date:  2012-12-10       Impact factor: 7.485

View more
  32 in total

1.  High glucose reduces megalin-mediated albumin endocytosis in renal proximal tubule cells through protein kinase B O-GlcNAcylation.

Authors:  Diogo de Barros Peruchetti; Rodrigo Pacheco Silva-Aguiar; Gabriela Marques Siqueira; Wagner Barbosa Dias; Celso Caruso-Neves
Journal:  J Biol Chem       Date:  2018-06-05       Impact factor: 5.157

Review 2.  Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.

Authors:  Chiara Lanzillotta; Fabio Di Domenico; Marzia Perluigi; D Allan Butterfield
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

3.  Expression of messenger RNA encoding two cellular metabolic regulators, AMP-activated protein kinase (AMPK) and O-GlcNAc transferase (OGT), in channel catfish: Their tissue distribution and relationship with changes in food intake.

Authors:  O Abernathy; D Kostner; P Buer; M Dougherty; A Schmidtberger; R Spainhour; A Leiker; M Vides; B Teel; Y Kobayashi
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2019-05-12       Impact factor: 2.320

Review 4.  Mass Spectrometry Approaches to Glycomic and Glycoproteomic Analyses.

Authors:  L Renee Ruhaak; Gege Xu; Qiongyu Li; Elisha Goonatilleke; Carlito B Lebrilla
Journal:  Chem Rev       Date:  2018-03-19       Impact factor: 60.622

5.  Deciphering the Functions of O-GlcNAc Glycosylation in the Brain: The Role of Site-Specific Quantitative O-GlcNAcomics.

Authors:  John W Thompson; Alexander W Sorum; Linda C Hsieh-Wilson
Journal:  Biochemistry       Date:  2018-07-02       Impact factor: 3.162

6.  Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment

Authors:  Po-Han Chen; Jimin Hu; Jianli Wu; Duc T Huynh; Timothy J Smith; Samuel Pan; Brittany J Bisnett; Alexander B Smith; Annie Lu; Brett M Condon; Jen-Tsan Chi; Michael Boyce
Journal:  JCI Insight       Date:  2019-11-26

Review 7.  Recent Advances in Glycoproteomic Analysis by Mass Spectrometry.

Authors:  Suttipong Suttapitugsakul; Fangxu Sun; Ronghu Wu
Journal:  Anal Chem       Date:  2019-11-04       Impact factor: 6.986

Review 8.  O-GlcNAcylation: the "stress and nutrition receptor" in cell stress response.

Authors:  Rui-Zhi Yao; Yang Liu; Shuai Lian; Peng Liu; Ya-Jie Hu; Hong-Zhao Shi; Hong-Ming Lv; Yu-Ying Yang; Bin Xu; Shi-Ze Li
Journal:  Cell Stress Chaperones       Date:  2020-11-07       Impact factor: 3.667

9.  Drosophila O-GlcNAcase Mutants Reveal an Expanded Glycoproteome and Novel Growth and Longevity Phenotypes.

Authors:  Ilhan Akan; Adnan Halim; Sergey Y Vakhrushev; Henrik Clausen; John A Hanover
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

10.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.